NON RARE IN EUROPE: Primary adult open-angle glaucoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:353225H40.1
Who is this for?
Show terms as
View depth
19Active trials8Treatment centers

Where are you in your journey?

UniteRare data is compiled from authoritative primary sources (FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, NORD), then processed through automated and AI-assisted extraction pipelines.
Report missing data

What is NON RARE IN EUROPE: Primary adult open-angle glaucoma?

Primary open-angle glaucoma (POAG) is the most common form of glaucoma in adults. It is a condition where the optic nerve at the back of the eye becomes gradually damaged, usually because the pressure inside the eye (called intraocular pressure) is too high. The drainage system of the eye slowly becomes less efficient over time, causing fluid to build up and pressure to increase. However, some people develop POAG even with normal eye pressure, which is called normal-tension glaucoma. POAG is often called the 'silent thief of sight' because it usually causes no pain and no noticeable symptoms in its early stages. Vision loss begins with peripheral (side) vision and slowly progresses inward. By the time a person notices vision changes, significant and irreversible damage may have already occurred. This is why regular eye exams are so important, especially after age 40. Treatment focuses on lowering eye pressure to slow or stop further nerve damage. This can be done with prescription eye drops, laser treatments, or surgery. While there is no cure and lost vision cannot be restored, early detection and consistent treatment can preserve remaining vision for most people. Several classes of medications are available, including prostaglandin analogs like latanoprost, beta-blockers like timolol, and newer agents like netarsudil. Laser trabeculoplasty and surgical options such as trabeculectomy or minimally invasive glaucoma surgery (MIGS) are also widely used.

Also known as:

Key symptoms:

Gradual loss of side (peripheral) visionTunnel vision in advanced stagesDifficulty seeing in dim lightingTrouble adjusting to dark roomsBlurred visionSeeing halos around lightsDifficulty with contrast sensitivityFrequent changes in eyeglass prescriptionEye pressure that is higher than normalLoss of central vision in very late stagesNo pain or symptoms in early stages

Inheritance
Multifactorial
Caused by a mix of several genes and environmental factors
Age of Onset
Adult
Begins in adulthood (age 18 or older)
Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Apr 2026Personalized Mobile Reminders for Medication Adherence and Intraocular Pressure Control in Primary Open-Angle Glaucoma

Sakarya Yenikent State Hospital — NA

TrialNOT YET RECRUITING
Mar 2026Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

Qlaris Bio, Inc. — PHASE2, PHASE3

TrialRECRUITING
Feb 2026Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options

Hospices Civils de Lyon

TrialRECRUITING
Nov 2025High-throughput Large-model-based AI-assisted Diagnosis Using OCT

Peking Union Medical College Hospital

TrialNOT YET RECRUITING
Nov 2025GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma

IVIEW Therapeutics Inc. — PHASE1, PHASE2

TrialRECRUITING
Oct 2025Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP)

Università degli Studi 'G. d'Annunzio' Chieti e Pescara — NA

TrialNOT YET RECRUITING
Sep 2025Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

Alcon Research — PHASE3

TrialACTIVE NOT RECRUITING
Aug 2025Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)

Qlaris Bio, Inc. — PHASE2

TrialACTIVE NOT RECRUITING
Jun 2025Study of Human Ocular Hemodynamics by Holography Dopple

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts — NA

TrialNOT YET RECRUITING
Apr 2025Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma

Okuvision GmbH — NA

TrialRECRUITING

Data is compiled from FDA regulatory filings and ClinicalTrials.gov, then processed through automated extraction; event classifications and dates may occasionally be misclassified. Verify against the linked FDA filing or trial record before clinical decisions. Updated periodically.

Treatments

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

No FDA-approved treatments are currently listed for NON RARE IN EUROPE: Primary adult open-angle glaucoma.

19 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

19 recruitingView all trials with filters →

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

Phase 32 trials
Nicotinamide Supplementation in Glaucoma
Phase 3
Enrolling by Invitation
· Sites: Singapore, Central Singapore; Singapore, Central Singapore · Age: 21+ years
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
Phase 3
Active — not recruiting
PI: Clinical Trial Lead, Pharma (Alcon Research, LLC) · Sites: Dothan, Alabama; Phoenix, Arizona +28 more · Age: 18+ years
Phase 42 trials
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
Phase 4
Actively Recruiting
PI: Study Director (Glaukos Corporation) · Sites: Kenosha, Wisconsin · Age: 45+ years
The OPTIMISE Study
Phase 4
Actively Recruiting
· Sites: Apeldoorn, Gelderland; Nijmegen, Gelderland +6 more · Age: 21+ years
Phase 22 trials
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
Phase 2
Active — not recruiting
PI: Lisa Brandano (Qlaris Bio, Inc.) · Sites: Seoul · Age: 30+ years
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
Phase 2
Active — not recruiting
· Sites: Palo Alto, California · Age: 18+ years
N/A5 trials
Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study
N/A
Actively Recruiting
PI: Doreen Schmidl, MD,PhD (Department of Clinical Pharmacology, Medical Unive) · Sites: Vienna, Vienna · Age: 18+ years
Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma
N/A
Actively Recruiting
PI: Katrin Lorenz, Prof. (Augenklinik und Poliklinik der Universitätsmedizin) · Sites: Mainz · Age: 40+ years
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
N/A
Actively Recruiting
PI: Allen Cheong, PhD (The Hong Kong Polytechnic University) · Sites: Hong Kong, Hong Kong · Age: 55–80 yrs
Changes in Eye Pressure in Glaucoma Patients Treated with Istent Inject W, Monitored by a Contact Lens Sensor
N/A
Actively Recruiting
· Sites: Barcelona, Spain; Barcelona, Spain · Age: 18+ years
Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.
N/A
Active — not recruiting
PI: Sabine Glibert (iSTAR Medical) · Sites: Glendale, Arizona; Fayetteville, Arkansas +35 more · Age: 46+ years
Other6 trials
INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma Register
Enrolling by Invitation
· Sites: Lausanne, Canton of Vaud · Age: 1+ years
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
Actively Recruiting
PI: Lyne Racette, PhD (University of Alabama at Birmingham) · Sites: Birmingham, Alabama · Age: 18+ years
Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options
Actively Recruiting
· Sites: Lyon · Age: 18+ years
Uddevalla Skövde Transscleral Micropulse Study
Enrolling by Invitation
PI: Tobias Dahlgren, MD (Vastra Gotaland Region) · Sites: Skövde, Västra Götaland County; Uddevalla, Västra Götaland County · Age: 18+ years
Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) Shunt
Actively Recruiting
· Sites: Tbilisi · Age: 40–90 yrs
Impact of Glaucoma and Visual Field Loss on Life Space
Active — not recruiting
PI: Lyne Racette, PhD (University of Alabama at Birmingham) · Sites: Birmingham, Alabama · Age: 18+ years

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

No specialists are currently listed for NON RARE IN EUROPE: Primary adult open-angle glaucoma.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

🏨 Children's

Children's Hospital Colorado Rare Disease Program

Children's Hospital Colorado

📍 Aurora, CO

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Boston Children's Hospital Rare Disease Program

Boston Children's Hospital

📍 Boston, MA

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

🏨 Children's

Ann & Robert H. Lurie Children's Hospital Genetics

Lurie Children's Hospital

📍 Chicago, IL

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

Cincinnati Children's Hospital Medical Center

Cincinnati Children's

📍 Cincinnati, OH

👤 Boston Children's Hospital Rare Disease Program

🏨 Children's

Nationwide Children's Hospital Rare Disease Center

Nationwide Children's Hospital

📍 Columbus, OH

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

Travel Grants

No travel grants are currently matched to NON RARE IN EUROPE: Primary adult open-angle glaucoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open NON RARE IN EUROPE: Primary adult open-angle glaucomaForum →

No community posts yet. Be the first to share your experience with NON RARE IN EUROPE: Primary adult open-angle glaucoma.

Start the conversation →

Latest news about NON RARE IN EUROPE: Primary adult open-angle glaucoma

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

No recent news articles for NON RARE IN EUROPE: Primary adult open-angle glaucoma.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How advanced is my glaucoma, and how much vision have I already lost?,What is my target eye pressure, and how will we know if treatment is working?,What are the side effects of the eye drops you are prescribing?,Should my family members be screened for glaucoma?,How often do I need to come in for check-ups?,If eye drops don't work well enough, what are my next treatment options?,Are there any lifestyle changes I can make to help protect my vision?

Common questions about NON RARE IN EUROPE: Primary adult open-angle glaucoma

What is NON RARE IN EUROPE: Primary adult open-angle glaucoma?

Primary open-angle glaucoma (POAG) is the most common form of glaucoma in adults. It is a condition where the optic nerve at the back of the eye becomes gradually damaged, usually because the pressure inside the eye (called intraocular pressure) is too high. The drainage system of the eye slowly becomes less efficient over time, causing fluid to build up and pressure to increase. However, some people develop POAG even with normal eye pressure, which is called normal-tension glaucoma. POAG is often called the 'silent thief of sight' because it usually causes no pain and no noticeable symptoms

How is NON RARE IN EUROPE: Primary adult open-angle glaucoma inherited?

NON RARE IN EUROPE: Primary adult open-angle glaucoma follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does NON RARE IN EUROPE: Primary adult open-angle glaucoma typically begin?

Typical onset of NON RARE IN EUROPE: Primary adult open-angle glaucoma is adult. Age of onset can vary across affected individuals.

Are there clinical trials for NON RARE IN EUROPE: Primary adult open-angle glaucoma?

Yes — 19 recruiting clinical trials are currently listed for NON RARE IN EUROPE: Primary adult open-angle glaucoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Frequently asked questions about NON RARE IN EUROPE: Primary adult open-angle glaucoma

Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.

  1. What is NON RARE IN EUROPE: Primary adult open-angle glaucoma?

    NON RARE IN EUROPE: Primary adult open-angle glaucoma is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:353225). It is typically inherited as multifactorial. Age of onset is generally adult. For verified primary sources, see the UniteRare NON RARE IN EUROPE: Primary adult open-angle glaucoma page.

  2. How is NON RARE IN EUROPE: Primary adult open-angle glaucoma inherited?

    NON RARE IN EUROPE: Primary adult open-angle glaucoma follows multifactorial inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.

  3. Are there FDA-approved treatments for NON RARE IN EUROPE: Primary adult open-angle glaucoma?

    Approved treatments for NON RARE IN EUROPE: Primary adult open-angle glaucoma are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.

  4. Are there clinical trials recruiting for NON RARE IN EUROPE: Primary adult open-angle glaucoma?

    UniteRare currently lists 19 clinical trials relevant to NON RARE IN EUROPE: Primary adult open-angle glaucoma sourced from ClinicalTrials.gov. Each trial entry includes recruitment status, eligibility criteria summary, principal-investigator information, and study locations. Patients should discuss eligibility with their healthcare provider before enrolling.

  5. How do I find a specialist for NON RARE IN EUROPE: Primary adult open-angle glaucoma?

    Verified NON RARE IN EUROPE: Primary adult open-angle glaucoma specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.

See full NON RARE IN EUROPE: Primary adult open-angle glaucoma page for complete clinical details, sources, and verified-specialist listings.

Cite this page

Select a citation format above to view and copy.